Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet

Clinical Science - Tập 119 Số 6 - Trang 239-250 - 2010
Vanessa Souza‐Mello1, Bianca Martins Gregório1, Fernando S. Cardoso-de-Lemos1, Laı́s de Carvalho1, Márcia Barbosa Águila1, Carlos Alberto Mandarim‐de‐Lacerda1
1Laboratory of Morphometry, Biomedical Center, Institute of Biology, State University of Rio de Janeiro, 20551-030 Rio de Janeiro, RJ, Brazil

Tóm tắt

The aim of the present study was to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, and pancreatic and hepatic remodelling in C57BL/6 mice fed on a very HF (high-fat) diet. Male C57BL/6 mice were fed on an HF (60% lipids) diet or SC (standard chow; 10% lipids) diet for 10 weeks, after which time the following drug treatments began: HF-T (HF diet treated with telmisartan; 5.2 mg·kg−1 of body weight·day−1), HF-S (HF diet treated with sitagliptin; 1.08 g·kg−1 of body weight·day−1), HF-M (HF diet treated with metformin; 310.0 mg·kg−1 of body weight·day−1), HF-TM (HF diet treated with telmisartan+metformin), HF-TS (HF diet treated with telmisartan+sitagliptin) and HF-SM (HF diet treated with sitagliptin+metformin). Treated groups also had free access to the HF diet, and treatments lasted for 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blot analysis and electron microscopy were used. The HF diet yielded an overweight phenotype, an increase in oral glucose intolerance, hyperinsulinaemia, hypertrophied islets and adipocytes, stage 2 steatosis (>33%), and reduced liver PPAR-α (peroxisome-proliferator-activated receptor-α) and GLUT-2 (glucose transporter-2) levels, concomitant with enhanced SREBP-1 (sterol-regulatory-element-binding protein-1) expression (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, a reversal of insulin resistance, islet and adipocyte hypertrophy, and alleviated hepatic steatosis. Only the HF-T and HF-TS groups had body weights similar to the SC group at the end of the experiment, and the latter treatment reversed hepatic steatosis. Increased PPAR-α immunostaining in parallel with higher GLUT-2 and reduced SREBP-1 expression may explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-α (tumour necrosis factor-α) levels (P<0.0001) in the drug-treated groups. In conclusion, all of the drug treatments were effective in controlling the metabolic syndrome. The best results were achieved using telmisartan and sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-γ agonism and PPAR-α activation in the liver with extended incretin action.

Từ khóa


Tài liệu tham khảo

Despres, 2006, Abdominal obesity and metabolic syndrome, Nature, 444, 881, 10.1038/nature05488

Marchesini, 2001, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844

Pitt, 2007, Hepato-pancreato-biliary fat: the good, the bad and the ugly, HPB, 9, 92, 10.1080/13651820701286177

Duvnjak, 2007, Pathogenesis and management issues for non-alcoholic fatty liver disease, World J. Gastroenterol., 13, 4539, 10.3748/wjg.v13.i34.4539

Pershadsingh, 2006, Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ, Int. J. Biochem. Cell Biol., 38, 766, 10.1016/j.biocel.2005.08.006

Home, 2008, Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents, Diabetes Obes. Metab., 10, 699, 10.1111/j.1463-1326.2007.00761.x

Ranganath, 2008, Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, J. Clin. Pathol., 61, 401, 10.1136/jcp.2006.043232

Gallou-Kabani, 2007, C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome, Obesity, 15, 1996, 10.1038/oby.2007.238

Schreyer, 1998, C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis, Atherosclerosis, 136, 17, 10.1016/S0021-9150(97)00165-2

Matthews, 1985, Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883

Mandarim-de-Lacerda, 2010, Image analysis and quantitative morphology, Methods Mol. Biol., 611, 211, 10.1007/978-1-60327-345-9_17

Aguila, 2003, Dietary effect of different high-fat diet on rat liver stereology, Liver Int., 23, 363, 10.1034/j.1478-3231.2003.00858.x

Gundersen, 1977, Notes on the estimation of the numerical density of arbitrary profiles: the edge effect, J. Microsc., 111, 219, 10.1111/j.1365-2818.1977.tb00062.x

Fernandes-Santos, 2009, Rosiglitazone aggravates nonalcoholic fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet, Pancreas, 38, e80, 10.1097/MPA.0b013e3181987d9d

Mandarim-de-Lacerda, 2003, Stereological tools in biomedical research, An. Acad. Bras. Cienc., 75, 469, 10.1590/S0001-37652003000400006

Araki, 2006, Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice, Hypertension, 48, 51, 10.1161/01.HYP.0000225402.69580.1d

Cohen, 2004, Effects of insulin-sensitising agents in mice with hepatic insulin resistance, Diabetologia, 47, 407, 10.1007/s00125-003-1320-4

Lamont, 2008, Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice, Diabetes, 57, 190, 10.2337/db07-1202

Benson, 2004, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity, Hypertension, 43, 993, 10.1161/01.HYP.0000123072.34629.57

Zanchi, 2007, Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties, Am. J. Physiol. Endocrinol. Metab., 293, E91, 10.1152/ajpendo.00024.2007

Yasuda, 2002, Enhanced secretion of glucagon-like peptide 1 by biguanide compounds, Biochem. Biophys. Res. Commun., 298, 779, 10.1016/S0006-291X(02)02565-2

Green, 2006, Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1, Eur. J. Pharmacol., 547, 192, 10.1016/j.ejphar.2006.07.043

Goodarzi, 2005, Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents, Diabetes Obes. Metab., 7, 654, 10.1111/j.1463-1326.2004.00448.x

Baggio, 2007, Biology of incretins: GLP-1 and GIP, Gastroenterology, 132, 2131, 10.1053/j.gastro.2007.03.054

Herman, 2006, Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes, Curr. Med. Res. Opin., 22, 1939, 10.1185/030079906X132587

Festi, 2004, Hepatic steatosis in obese patients: clinical aspects and prognostic significance, Obes. Rev., 5, 27, 10.1111/j.1467-789X.2004.00126.x

Geerts, 2001, History, heterogeneity, developmental biology and functions of quiescent hepatic stellate cells, Semin. Liver Dis., 21, 311, 10.1055/s-2001-17550

Hui, 2003, Molecular basis of hepatic fibrosis, Expert Rev. Mol. Med., 5, 1, 10.1017/S1462399403005684

Friedman, 2008, Mechanisms of hepatic fibrogenesis, Gastroenterology, 134, 1655, 10.1053/j.gastro.2008.03.003

Svegliati-Baroni, 2006, A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury, Am. J. Pathol., 169, 846, 10.2353/ajpath.2006.050953

Nabeshima, 2009, Deletion of angiotensin II type I receptor reduces hepatic steatosis, J. Hepatol., 50, 1226, 10.1016/j.jhep.2009.01.018

Ibdah, 2005, Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance, Gastroenterology, 128, 1381, 10.1053/j.gastro.2005.02.001

Petersen, 2006, Etiology of insulin resistance, Am. J. Med., 119, S10, 10.1016/j.amjmed.2006.01.009

Ellingsgaard, 2008, Interleukin-6 regulates pancreatic α-cell mass expansion, Proc. Natl. Acad. Sci. U.S.A., 105, 13163, 10.1073/pnas.0801059105

Winzell, 2007, Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet, Diabetologia, 50, 1453, 10.1007/s00125-007-0675-3

Sharma, 2002, Angiotensin blockade prevents type 2 diabetes by formation of fat cells, Hypertension, 40, 609, 10.1161/01.HYP.0000036448.44066.53

Kudo, 2009, Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue, Liver Int., 27, 988, 10.1111/j.1478-3231.2009.02006.x

Ren, 2006, Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-α or isoproterenol, J. Mol. Endocrinol., 37, 175, 10.1677/jme.1.02061

Boschmann, 2009, Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients, J. Clin. Endocrinol. Metab., 94, 846, 10.1210/jc.2008-1400

Thông tin
Thông tin xuất bản

Clinical Science

Tập 119 Số 6

239-250

Thông tin tác giả